Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease

Bessissow, Talat; Le, Ngoc Han; Rollet, Kathleen; Afif, Waqqas; Bitton, Alain; Sebastiani, Giada

doi:10.1097/mib.0000000000000832

Cited by 95 publications

(130 citation statements)

References 47 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Similar association have been made between psoriasis and NAFLD[28]. Duration of IBD was another independent predictor of development of NAFLD in the aforementioned Bessissow et al[22] study. Longer disease duration exposes patients to multiple risk factors for NAFLD, including chronic relapsing inflammation, alteration of gut microbiota and hepatotoxic drugs.…”

Section: Pathogenesissupporting

confidence: 75%

See 1 more Smart Citation

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Chen

Battat

Khoury

et al. 2016

WJG

Self Cite

View full text Add to dashboard Cite

Emerging data have highlighted the co-existence of non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent disorders with significant complications and impact on future health burden. Cross-section observational studies have shown widely variable prevalence rates of co-existing disease, largely due to differences in disease definition and diagnostic tools utilised in the studies. Age, obesity, insulin resistance and other metabolic conditions are common risks factors in observational studies. However, other studies have also suggested a more dominant role of inflammatory bowel disease related factors such as disease activity, duration, steroid use and prior surgical intervention, in the development of NAFLD. This suggests a potentially more complex pathogenesis and relationship between the two diseases which may be contributed by factors including altered intestinal permeability, gut dysbiosis and chronic inflammatory response. Commonly used immunomodulation agents pose potential hepatic toxicity, however no definitive evidence exist linking them to the development of hepatic steatosis, nor are there any data on the impact of therapy and prognosis in patient with co-existent diseases. Further studies are required to assess the impact and establish appropriate screening and management strategies in order to allow early identification, intervention and improve patient outcomes.

show abstract

Section: Pathogenesissupporting

confidence: 75%

“…A study from our group using the validated hepatic steatosis index (HSI) longitudinally followed 321 IBD patients over 7 years (217 CD, 104 UC)[22]. HSI, defined as: 8 × AST/ALT + BMI (+2, if female; +2, if diabetes), was applied to diagnose hepatic steatosis if the score is ≥ 36.…”

Section: Epidemiology: Prevelance Of Nafld In Ibdmentioning

confidence: 99%

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Chen

Battat

Khoury

et al. 2016

WJG

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study reported an even higher incidence rate of NAFLD in IBD patients without underlying liver disease, using the validated Hepatic Steatosis Index . NAFLD was reported in one‐third of the patients, accounting for an incidence rate of 9.1/100 patient‐years (95% CI, 7.4‐10.9), which is higher than the general population (.029‐3.1/100 patient‐years).…”

Section: Other Hepatic Manifestations Than Psc Affecting Ibd Patientsmentioning

confidence: 99%

“…Duration of IBD is probably another independent predictor of NAFLD development . Disease exposes patients to multiple risk factors for NAFLD, including chronic relapsing inflammation, alteration of gut microbiota and hepatotoxic drugs.…”

Section: Other Hepatic Manifestations Than Psc Affecting Ibd Patientsmentioning

confidence: 99%

Hepatic manifestations of inflammatory bowel diseases

Restellini

Chazouillères

Frossard

2016

Liver International

View full text Add to dashboard Cite

Inflammatory bowel diseases are associated with various hepatobiliary disorders, reported both in Crohn's disease and ulcerative colitis. They may occur at any moment in the natural course of the disease. The prevalence of liver dysfunction rises from 3% to 50% accordingly to definitions used in different studies. Fatty liver is considered as the most common hepatobiliary complication in inflammatory bowel diseases while primary sclerosing cholangitis is the most specific one. Less frequently, inflammatory bowel diseases-associated hepatobiliary disorders include: autoimmune hepatitis/ primary sclerosing cholangitis overlap syndrome, IgG4-associated cholangiopathy, primary biliary cholangitis, hepatic amyloidosis, granulomatous hepatitis, cholelithiasis, portal vein thrombosis and liver abscess. The spectrum of these manifestations varies according to the type of inflammatory bowel diseases. Treatments of inflammatory bowel diseases may cause liver toxicity, although incidence of serious complications remains low. However, early diagnosis of drug-induced liver injury is of major importance as it affects future clinical management. When facing abnormal liver tests, clinicians should undertake a full diagnostic work-up in order to determine whether the hepatic abnormalities are related to the inflammatory bowel diseases or not.Management of hepatic manifestations in inflammatory bowel diseases usually involves both hepatologists and gastroenterologists because of the complexity of some situations. K E Y W O R D Sdrug-induced liver injury, hepatotoxicity, inflammatory bowel disease, liver disease, primary sclerosing cholangitis

show abstract

“…The rate of NAFLD likely depends on environmental and genetic risk factors of study population, as a recent prospective Swedish study detected lower rates of NAFLD than American studies [53]. Disease specific risk factors for NAFLD in patients with IBD include small bowel surgery, use of steroids, and disease duration and activity [52, 54]. As the prevalence of NAFLD and subsequently nonalcoholic steatohepatitis induced cirrhosis, increases in patients with IBD, liver failure, and transplantation will complicate management of patients with IBD.…”

Section: Comorbiditiesmentioning

confidence: 99%

The Changing Phenotype of Inflammatory Bowel Disease

Moran

Sheehan

Shanahan

2016

Gastroenterology Research and Practice

View full text Add to dashboard Cite

It is widely known that there have been improvements in patient care and an increased incidence of Inflammatory Bowel Disease (IBD) worldwide in recent decades. However, less well known are the phenotypic changes that have occurred; these are discussed in this review. Namely, we discuss the emergence of obesity in patients with IBD, elderly onset disease, mortality rates, colorectal cancer risk, the burden of medications and comorbidities, and the improvement in surgical treatment with a decrease in surgical rates in recent decades.

show abstract

Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease

Cited by 95 publications

References 47 publications

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article

Hepatic manifestations of inflammatory bowel diseases

The Changing Phenotype of Inflammatory Bowel Disease

Contact Info

Product

Resources

About